Cardiology

Shagun Bindlish, MD, board member of the American Diabetes Association, discusses challenges to diagnosing and treating venous disease in patients with obesity.

A new study reveals that noninvasive LVEDP screening can enhance heart failure detection and improve patient outcomes in primary care settings.

The Advisory Panel laid out 4 priority actions for clinicians, policy makers, and industry.

Your daily dose of the clinical news you may have missed.

Adequate sleep tops the 4 elements most important to CV health after menopause, with blood pressure, glucose levels, and smoking status close behind.

Inclisiran can now be used without a background statin, as an adjunct to changes in diet and physical activity for reduction of LDL-C in hypercholesterolemia.

In the SURPASS-CVOT trial, tirzepatide reduced MACE-3 by 8% and all-cause mortality by 16% compared with dulaglutide, while also reducing HbA1c and weight.

Obesity medicine specialist Monu Khanna, MD, discusses the critical role of primary care in obesity-related risk reduction through lifestyle, behavior, and emerging therapies.

Monu Khanna, MD, offers 3 takeaways for primary care: address obesity as root cause, reduce stigma, and explore new treatments to reduce cardiovascular risk.

Dr Khanna discusses how PCPs can use patient relationships to tailor lifestyle advice and manage obesity-related cardiometabolic disease.

FDA approval based on FINEARTS-HF trial showing 16% risk reduction in CV death and HF events.

These new FDA-approved drugs include treatments for migraine, chronic spontaneous urticaria, RSV, and more.

GLP-1 medications are transforming obesity medicine but strong evidence points to a need for integrating nutrition and lifestyle support for lasting weight loss and health benefits.

Body fat percentage and waist circumference were both significantly associated with 15-year all-cause mortality while BMI had no significant association.

Weight cycling significantly raises heart failure and metabolic disease risks, independent of baseline overweight, underscoring the importance of stable weight strategies.

ADA 2025: Insulin efsitora proved noninferior to daily insulin glargine for reducing HbA1c, resulted in fewer episodes of hypoglycemia, and required fewer dose adjustments.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Huxley Medical's SANSA home sleep apnea test matched traditional PSG in accuracy and significantly simplifies OSA assessment and diagnosis for patients and HCPs.

Research presented at ACOG 2025 showed 99% of pregnant women included in the analysis were eligible for aspirin, per ACOG guidelines.

For individuals with T2D, findings are more than numeric; a 5-mm Hg reduction in SBP reduces stroke risk by 14%, CV events by 6%, and heart failure by 8%, authors wrote.

The novel triple fixed-dose combination of telmisartan, amlodipine and indapamide, is the first of its kind approved for initial treatment of hypertension.

Research reveals that the quality of foods in low-carb and low-fat diets significantly impacts heart health, emphasizing whole, plant-based options.

Adults with both HTN and T2D had more than twice the risk of all-cause mortality and nearly three times the risk of cardiovascular mortality, according to new data.

For every 10% increase in energy from high-quality carbohydrates, the odds of healthy aging rose by 31%, according to an analysis of data from the Nurse's Health Study.

ESOC 2025: New research reveals that combined oral contraceptive use significantly increases the risk of cryptogenic stroke in young women, urging careful assessment by clinicians.

Semaglutide was associated with a significant reduction in risk for major adverse cardiovascular events after just 3 months of treatment in a population with established CVD.

Any increase in lipoprotein(a) levels was linked to increased risk of myocardial infarction and stroke; women and Black adults are most likely to be affected.

Low-dose clorthalidone offers clinicians a new option for initiating treatment that may mitigate well-known metabolic adverse effects.